Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA +3.48%28 Current Ratio is 7.42 as of Mar. 2026, which is 8% above its 10-year median of 6.90. GuruFocus rates XSAT:CESSA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Cessatech AS ranks better than 69.95% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cessatech AS's current ratio for the quarter that ended in Mar. 2026 was 7.42.
Cessatech AS has a current ratio of 7.42. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cessatech AS's Current Ratio or its related term are showing as below:
XSAT:CESSA'
s Current Ratio Range Over the Past 10 Years
Min: 0.8 Med: 6.9 Max: 69.71
Current: 7.42
During the past 6 years, Cessatech AS's highest Current Ratio was 69.71. The lowest was 0.80. And the median was 6.90.
XSAT:CESSA's Current Ratio is ranked better than 69.95% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs XSAT:CESSA: 7.42
Cessatech AS (XSAT:CESSA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cessatech AS Current Ratio Related Terms
Cessatech AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Cessatech AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Cessatech AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cessatech AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (XSAT:CESSA) has a Current Ratio of 7.42 as of Mar. 2026. This is near median its historical median of 6.90. Over the past decade, Cessatech AS's Current Ratio has ranged from 0.80 to 69.71. According to the industry distribution chart, Cessatech AS ranks #424 out of 1411 companies in the Biotechnology industry, placing it in the top 30%.
Is Cessatech AS's Current Ratio too high?
Cessatech AS's current Current Ratio of 7.42 is near median its 10-year median of 6.90. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 69.71. The Biotechnology industry median Current Ratio is 3.85. Cessatech AS's value of 7.42 is 92.7% above this industry median. Based on the distribution chart, Cessatech AS ranks #424 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #424 out of 1411 companies for Current Ratio. This puts Cessatech AS in the upper half of its industry. The industry median Current Ratio is 3.85. Cessatech AS's value of 7.42 is 92.7% above this benchmark. Historically, Cessatech AS's own Current Ratio has ranged from 0.80 to 69.71 over the past decade. While the company's 10-year median is 6.90 vs. the industry median of 3.85, Cessatech AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cessatech AS's current Current Ratio of 7.42 is 92.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cessatech AS's current Current Ratio is 7.42, which is near median its own 10-year median of 6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current Current Ratio of 7.42. The current Current Ratio is 7.42, which is near median its 10-year median of 6.90 and 92.7% above the Biotechnology industry median of 3.85. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current Current Ratio is 7.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score
Get the complete analysis for XSAT:CESSA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
